Clinical Trial Update: A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis [Phase 2]

View source ↗

Summary

An update on a Phase 2 trial evaluating AK111 for moderate-to-severe psoriasis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• AK111

Snippet

Sponsor: Akeso | Conditions: Psoriasis | Phase 2 | Status: COMPLETED